We are pleased to share the significant progress Proteon Pharmaceuticals made in 2024. Our company strengthened its market position, advanced its research initiatives, and expanded its manufacturing capabilities whilst continuing to develop innovative bacteriophage solutions for animal health and food safety.
Key Developments
Manufacturing and Operations
In a significant step towards expanding our global reach, March inaugurated our new manufacturing facility in India. This state-of-the-art facility enhances our production capabilities in the Asian market, ensuring more efficient delivery of bacteriophage solutions to our growing regional customer base. The facility represents a crucial component in our strategy to build a robust, global supply chain network.
Research and Development
Our R&D team has been busy this year, with several noteworthy publications released in May. The team published new research on multiplex-PCR methodology for E. coli detection, which has enhanced our capabilities in bacterial strain identification.
We also developed a new PCR test for mastitis diagnosis that uses NGS (Next-Generation Sequencing) data, providing dairy farmers with an improved tool for herd health management.
Adding to these developments, we received a patent grant from the European Patent Office for our diagnostic technology targeting Avian Pathogenic E. coli in poultry. This recognition validates our innovative approach to disease detection methods.
Regulatory Progress
The year brought two major regulatory achievements. In August, Brazil’s Ministry of Agriculture (MAPA) approved the registration of our product BAFACOL B – to protect poultry flocks from colibacillosis caused by Avian Pathogenic E. coli (APEC). In October, MAPA also approved the registration of BAFASAL PRO, opening new opportunities in one of the world’s largest poultry markets. This was followed in December by a pivotal European Food Safety Authority (EFSA) scientific opinion validating BAFASAL®’s efficacy in reducing Salmonella Enteritidis in poultry production, a crucial step towards European market authorisation.
Industry Leadership
Throughout the year, Proteon maintained its position at the forefront of bacteriophage technology development. In February, Prof. Jarosław Dastych shared valuable insights at the 6th Bacteriophage Therapy Summit, addressing the European regulatory landscape. His appointment as the inaugural President of PhageEU in July further strengthened our role in shaping European bacteriophage development initiatives. The year concluded with our participation in a significant European Parliament debate on antimicrobial resistance in December, contributing to crucial policy discussions.
Scientific Engagement and Development
Our team actively participated in key industry events throughout 2024, showcasing our commitment to scientific advancement.
The year began with our attendance at Animal Health, Nutrition and Technology Innovation Europe in February, followed by the Agri-Food Summit in San Francisco in March. In June, we participated in the Animal Health, Nutrition & Technology Innovation USA conference and also the XXVII Poultry Symposium in Poland, where we shared insights on poultry farm pathogen management.
October saw us at the Animal AgTech Innovation Summit in Amsterdam, while in November, our Indian team represented Proteon at Poultry India 2024, strengthening our presence in the regional market.
The year 2024 demonstrated consistent advancement for Proteon Pharmaceuticals in bacteriophage technology development and operational growth. Our research teams continued their dedicated work on creating effective solutions for animal health and food safety, particularly focusing on antimicrobial resistance challenges. The company’s presence at key industry events, significant regulatory achievements, and research publications establish a robust foundation for our continued work in sustainable agricultural solutions.
